Policy & Regulation
US FDA extends review timeline for AstraZeneca's camizestrant application
27 May 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) announced on Wednesday that the US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee...
Circio and AaviGen partner to develop next-generation gene therapies for heart disease
27 May 2026 - Biotechnology companies Circio Holding ASA (OSE:CRNA) and AaviGen GmbH on Wednesday announced a research collaboration to develop circVec-enhanced AAV vectors engineered for targeted, lo...
CordenPharma acquires AmbioPharm, expanding peptide API capacity
27 May 2026 - CordenPharma, a Switzerland-based global Contract Development and Manufacturing Organisation (CDMO), announced on Wednesday that it has entered into an agreement to acquire AmbioPharm, a...
OncoZenge secures European approval for Phase III BEAM-Pain trial of BupiZenge
26 May 2026 - Swedish pharmaceutical company OncoZenge AB (Nasdaq First North Growth Market:ONCOZ) announced on Tuesday that it has received European regulatory approval to initiate its pivotal Phase ...
AstraZeneca's Enhertu recommended for EU approval in HER2-positive solid tumours
...
Lundbeck's Vyepti (eptinezumab) receives South Korean approval for preventive treatment of migraine
26 May 2026 - Danish biopharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) announced on Tuesday that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing authorisation for...